MA48863A - Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées - Google Patents
Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associéesInfo
- Publication number
- MA48863A MA48863A MA048863A MA48863A MA48863A MA 48863 A MA48863 A MA 48863A MA 048863 A MA048863 A MA 048863A MA 48863 A MA48863 A MA 48863A MA 48863 A MA48863 A MA 48863A
- Authority
- MA
- Morocco
- Prior art keywords
- tgf
- fusion proteins
- receptor fusion
- beta type
- related uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501229P | 2017-05-04 | 2017-05-04 | |
| PCT/US2018/030816 WO2018204594A1 (fr) | 2017-05-04 | 2018-05-03 | Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA48863A true MA48863A (fr) | 2020-04-01 |
| MA48863B1 MA48863B1 (fr) | 2023-08-31 |
Family
ID=88016828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA48863A MA48863B1 (fr) | 2017-05-04 | 2018-05-03 | Protéines de fusion du récepteur tgf-bêta de type ii et utilisations associées |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA48863B1 (fr) |
-
2018
- 2018-05-03 MA MA48863A patent/MA48863B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA48863B1 (fr) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3628049T3 (da) | Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf | |
| DK3280727T3 (da) | Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf | |
| MA44986A (fr) | Protéines de fusion gdf15 et leurs utilisations | |
| DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
| KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
| MA51291A (fr) | Protéines de fusion il-2 fc modifiées | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| MA46534A (fr) | Protéines de fusion fc hétérodimères il15/il15r | |
| DK3292141T3 (da) | Fusionsproteiner | |
| DK3458479T3 (da) | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater | |
| DK3365364T5 (da) | Kimære antistof/T-celle-receptorkonstruktioner og anvendelser deraf | |
| BR112018004981A2 (pt) | anticorpos anti-pró-miostatina/miostatina latente e usos destes. | |
| BR112017024757A2 (pt) | composições e métodos para reprogramação de tcr utilizando proteínas de fusão | |
| BR112017021040A2 (pt) | anticorpos dirigidos contra proteína mucina e imunoglobulina de célula t3 (tim-3) | |
| DK3180363T3 (da) | Sirp-alpha-immunoglobulin fusionsproteiner | |
| DK3307274T3 (da) | Anti-cd123-antistoffer og konjugater deraf | |
| DK3463435T3 (da) | Alpha-synuklein-antistoffer og anvendelser deraf | |
| DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| DK3275895T3 (da) | Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf | |
| DK3402821T5 (da) | Psma-bindende antistof og anvendelser deraf | |
| MA50908A (fr) | Formulations de protéines de fusion vegfr-fc | |
| CL2016001921A1 (es) | Proteínas inmovilizadas y uso de las mismas | |
| IL297395B1 (en) | btla fusion protein agonists and uses thereof | |
| ZA202003845B (en) | Fusion proteins |